Printer Friendly

Zydus Cadila granted final FDA approval to commercialise Memantine Hydrochloride.

M2 PHARMA-July 12, 2017-Zydus Cadila granted final FDA approval to commercialise Memantine Hydrochloride


India-based multinational pharmaceutical firm Zydus Cadila has been granted final approval from the US Food and Drug Administration (FDA) to commercialise Memantine Hydrochloride tablets in the United States, its listed entity Cadila Healthcare (NSE: CADILHC) reported on Wednesday.

Memantine Hydrochloride is used to treat dementia and is indicated in dosages of 5mg and 10mg tablets.

The company has said that the drug will be manufactured at its plant in Moraiya, Ahmedabad.

This is the latest of more than 120 approvals for the company.

Dementia is a chronic disorder that attacks mental processes, resulting in memory loss, personality changes and impaired reasoning.

Researchers at Alzheimer's Disease International estimate that there are nearly 50 million people worldwide living with dementia - a number set to double every 20 years due to the world's ageing population.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 12, 2017
Previous Article:ERYTECH Pharma forms research collaboration with Queen's University to develop treatment for arginase-1 deficiency.
Next Article:Biocartis devices exempt from US FDA 510(k) notification requirements.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |